Gynaecologic Oncology Society of Kenya (GOSK) clinical management protocol for malignant ovarian germ cell tumors in Kenya - 2026

Objective: To develop a standardized, evidence-based national clinical management protocol for malignant ovarian germ cell tumors in Kenya, under the auspices of the Gynaecologic Oncology Society of Kenya (GOSK). The protocol addresses diagnosis and diagnostic workup, stage-specific surgical and adjuvant management, follow-up and surveillance, management of recurrent and chemoresistant disease, and supportive and palliative care. Methods: A guideline-adaptation methodology was used. A multidisciplinary panel convened by GOSK conducted a systematic search of PubMed and Google Scholar to identify existing international guidelines on MOGCT management. Six candidate guidelines were retrieved and independently appraised by 2 trained panelists using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument across 6 quality domains. A tiebreaker mechanism was used to resolve disagreements. Guidelines that did not meet the prespecified thresholds for rigor of development and clarity of presentation were excluded. Recommendations from the retained guidelines were synthesized and contextualized to the Kenyan health care system and available resources. Results: Of the 6 guidelines appraised, the following were evaluated: the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology; the American Society of Clinical Oncology (ASCO) guidelines; the British Gynaecological Cancer Society (BGCS) guidelines; the European Society of Gynaecological Oncology (ESGO) guidelines; the European Society for Medical Oncology (ESMO) guidelines; and the guidelines of the Council for Medical Schemes (CMS/PBS). Four guidelines (NCCN, ASCO, BGCS, and ESGO) met the prespecified quality thresholds and were retained for adaptation. The resulting protocol provides recommendations on clinical presentation and imaging; tumor marker and histopathological evaluation; fertility-sparing surgery and comprehensive surgical staging for early-stage disease; bleomycin, etoposide, and cisplatin (BEP)-based adjuvant and first-line chemotherapy for advanced disease; structured follow-up over a minimum 5-year surveillance period; management of recurrent and chemoresistant disease according to platinum sensitivity; and early integration of psychosocial and palliative support. Recommendations: This protocol represents the first standardized, adapted, evidence-based national guideline for the management of malignant ovarian germ cell tumors in Kenya. Its adoption is anticipated to harmonize clinical practice, improve diagnostic accuracy and treatment outcomes, support the efficient use of limited resources, and reduce disparities in the quality of care delivered to this young and vulnerable patient population.

Authors

Institutions

Publication Details

Journal
Journal of Obstetrics and Gynaecology of Eastern and Central Africa
Published
2026-11-14
DOI
https://doi.org/10.59692/fhn9g641
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gynaecologic Oncology Society of Kenya (GOSK) clinical management protocol for malignant ovarian germ cell tumors in Kenya - 2026

Innocent O. Maranga, Rose Jepchumba Kosgei, Naomi sitati, Millicent Masinde et al.
Journal of Obstetrics and Gynaecology of Eastern and Central Africa
Ovarian cancer diagnosis and treatment
article

Gynaecologic Oncology Society of Kenya (GOSK) clinical management protocol for malignant ovarian germ cell tumors in Kenya - 2026

Innocent O. Maranga, Rose Jepchumba Kosgei, Naomi sitati, Millicent Masinde, Eunice Cheserem, Steven Ibua, Diana Marion, Margaret Kilonzo, Stella Njenga, Alfred Mokomba, Wycliffe Musalia, Victor Otieno, Anwar Mohamed, Jacqueline Chesang', Bruce Semo, Simon Gitau, Gideon Mutua, Benjamin Odongo, Isaac Maingi, Gonzaga Ngonyani, Francis Abinya
article en

Abstract

Objective: To develop a standardized, evidence-based national clinical management protocol for malignant ovarian germ cell tumors in Kenya, under the auspices of the Gynaecologic Oncology Society of Kenya (GOSK). The protocol addresses diagnosis and diagnostic workup, stage-specific surgical and adjuvant management, follow-up and surveillance, management of recurrent and chemoresistant disease, and supportive and palliative care. Methods: A guideline-adaptation methodology was used. A multidisciplinary panel convened by GOSK conducted a systematic search of PubMed and Google Scholar to identify existing international guidelines on MOGCT management. Six candidate guidelines were retrieved and independently appraised by 2 trained panelists using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument across 6 quality domains. A tiebreaker mechanism was used to resolve disagreements. Guidelines that did not meet the prespecified thresholds for rigor of development and clarity of presentation were excluded. Recommendations from the retained guidelines were synthesized and contextualized to the Kenyan health care system and available resources. Results: Of the 6 guidelines appraised, the following were evaluated: the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology; the American Society of Clinical Oncology (ASCO) guidelines; the British Gynaecological Cancer Society (BGCS) guidelines; the European Society of Gynaecological Oncology (ESGO) guidelines; the European Society for Medical Oncology (ESMO) guidelines; and the guidelines of the Council for Medical Schemes (CMS/PBS). Four guidelines (NCCN, ASCO, BGCS, and ESGO) met the prespecified quality thresholds and were retained for adaptation. The resulting protocol provides recommendations on clinical presentation and imaging; tumor marker and histopathological evaluation; fertility-sparing surgery and comprehensive surgical staging for early-stage disease; bleomycin, etoposide, and cisplatin (BEP)-based adjuvant and first-line chemotherapy for advanced disease; structured follow-up over a minimum 5-year surveillance period; management of recurrent and chemoresistant disease according to platinum sensitivity; and early integration of psychosocial and palliative support. Recommendations: This protocol represents the first standardized, adapted, evidence-based national guideline for the management of malignant ovarian germ cell tumors in Kenya. Its adoption is anticipated to harmonize clinical practice, improve diagnostic accuracy and treatment outcomes, support the efficient use of limited resources, and reduce disparities in the quality of care delivered to this young and vulnerable patient population.

Journal of Obstetrics and Gynaecology of Eastern and Central AfricaVol. 38(3)
University of Nairobi (KE), Kenyatta University (KE), Kenyatta National Hospital (KE), Amref Health Africa (KE), Amref International University (KE)
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon